NASDAQ : SLS
SELLAS Life Sciences Group, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.155 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.05B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.95B |
| Enterprise Value | 1.82B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 201.95M |
| Shares Outstanding | 201.95M |
| Shares Change (YoY) | +86.04% |
| Shares Change (QoQ) | +9.68% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 37.31% |
| Float | 201.15M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 14.20 |
| P/TBV Ratio | 14.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 18.83 |
| Quick Ratio | 18.28 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -39.63% |
| Return on Assets (ROA) | -23.30% |
| Return on Invested Capital (ROIC) | -25.05% |
| Return on Capital Employed (ROCE) | -24.03% |
| Weighted Average Cost of Capital (WACC) | 18.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.50M |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.57 |
| 52-Week Price Change | +365.39% |
| 50-Day Moving Average | 12.16 |
| 200-Day Moving Average | 8.57 |
| Relative Strength Index (RSI) | 38.66 |
| Average Volume (20 Days) | 6,740,050 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 53.76M |
| Short Previous Month | 55.13M |
| Short % of Shares Out | 26.62% |
| Short % of Float | 26.73% |
| Short Ratio (days to cover) | 10.31 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.12M |
| Pretax Income | -32.46M |
| Net Income | -32.46M |
| EBITDA | n/a |
| EBIT | -33.12M |
| Earnings Per Share (EPS) | -$0.21 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 138.34M |
| Total Debt | 737,000 |
| Net Cash | 137.61M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 137.66M |
| Book Value Per Share | 0.68 |
| Working Capital | 134.94M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -28.42M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -28.42M |
| FCF Per Share | -$0.14 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -86.04% |
| Shareholder Yield | -86.04% |
| Earnings Yield | -2.19% |
| FCF Yield | -1.45% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $32.50 |
| Price Target Difference | 235.74% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 8, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |